Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Early Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT05879432Phase 2Recruiting

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Role: lead

NCT04402957Phase 2Completed

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Role: lead

NCT03772678Early Phase 1Completed

A Phase I Study to Evaluate LSALT Peptide

Role: lead

NCT04330690Phase 3Unknown

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Role: collaborator

All 4 trials loaded